BCG in the Immunotherapy of Non-Hodgkin’s Malignant Lymphomas:Preliminary Results of a Controlled Trial

  • B. Hœrni
  • M. Durand
  • A. de Mascarel
  • P. Richaud
  • G. Hœrni-Simon
  • J. Chauvergne
  • C. Lagarde
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 65)

Abstract

In a previous paper, we presented our current results of a randomized trial of the efficacy of BCG to maintain complete remission in patients with malignant lymphoma in whom complete remission had previously been induced by an association of chemo- and radiotherapy [3]. There was a significant difference in the duration of complete remission in favor of patients treated with BCG scarifications as compared with the control group; this difference was about the same for patients with Hodgkin’s disease (who constituted two-thirds of the patients) and for the other patients suffering from non-Hodgkin’s lymphoma. We have concluded that BCG may be useful in maintaining complete remission and that a 3-year treatment seems sufficient. After obtaining these results, we continued this trial for non-Hodgkin’s lymphomas, and we present here the current results of this study.

Keywords

Lymphoma Cyclophosphamide Stein Prednisone Vincristine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chauvergne, J., Durand, M., Hœrni, B., Hœrni-Simon, G., Brunet, R., Lagarde, C.: Induction chemotherapy of non-Hodgkin’s malignant lymphomas. Eur. J. Cancer, 73, 399–400 (1977)Google Scholar
  2. 2.
    Chauvergne, J., Hœrni, B., Durand, M., Hœrni-Simon, G., Lagarde, C.: Chimiothérapie des réticulosarcomes. Résultats d’un essai contrôlé portant sur 60 malades. Nouv. Presse Med., 2, 2039- 2042 (1973)PubMedGoogle Scholar
  3. 3.
    Hœrni, B., Chauvergne, J., Hœrni-Simon, G., Durand, M., Lagarde, C.: BCG in the immunotherapy of malignant lymphomas. Current results of a controlled trial. Cancer Immunol. Immunother.,3, 57–60 (1977)CrossRefGoogle Scholar
  4. 4.
    Lennert, K., Stein, H., Kaiserling, E.: Cytological and functional criteria for the classification of malignant lymphomas. Br. J. Cancer, 31, Suppl. II, 29–43 (1975)Google Scholar
  5. 5.
    Mathé, G., Amiel, J. L., Schwarzenberg, L. et al.: Les diverses approches immunologiques du traitement des cancers humains, XXXVIIe Congr. Fr. Med., Paris, Masson pub. 1969Google Scholar
  6. 6.
    Mathé, G., Belpomme, D., Pouillart, P., Schwarzenberg, L., Misset, J. L., Jasmin, C., Musset, M., Cattan, A., Amiel, J. L., Schneider, M.: Preliminary results of an immunotherapy trial on terminal leukaemic lymphosarcoma. Biomedicine, 23,465–461 (1975)PubMedGoogle Scholar
  7. 7.
    Rosenberg, S. A.: Report of the committee on the staging of Hodgkin’s disease. Cancer Res., 26,1310 (1966)Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1978

Authors and Affiliations

  • B. Hœrni
  • M. Durand
  • A. de Mascarel
  • P. Richaud
  • G. Hœrni-Simon
  • J. Chauvergne
  • C. Lagarde

There are no affiliations available

Personalised recommendations